PGFC
SABS icon

Peapack-Gladstone Financial Corp’s SAB Biotherapeutics SABS Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,230
Closed -$36K – 715
2023
Q4 		$36K Hold
5,230
– – ﹤0.01% 691
2023
Q3 		$33K Hold
5,230
– – ﹤0.01% 685
2023
Q2 		$43K Buy
+5,230
New +$42.8K ﹤0.01% 696

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Peapack-Gladstone Financial Corp's SABS Position: Q1 2024 in Review

Peapack-Gladstone Financial Corp sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 5,230 shares — an estimated $36K sold.

Peapack-Gladstone Financial Corp first reported a position in SABS in Q2 2023 and held it in 3 quarters. The position peaked at $43K in Q2 2023. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • Peapack-Gladstone Financial Corp reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Peapack-Gladstone Financial Corp sold 5,230 SAB Biotherapeutics shares in Q1 2024, an estimated $36K.
  • Peapack-Gladstone Financial Corp first reported a position in SAB Biotherapeutics in Q2 2023 and held it in 3 quarters.
  • Peapack-Gladstone Financial Corp's SAB Biotherapeutics position peaked at $43K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2024, filed 10 May 2024.